Condition

Carcinoma, Non-small-cell Lung

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting0
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in ArgentinaNCT03321695 · 2017-12-27
COMPLETED
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsNCT03261947 · 2017-10-25
COMPLETED
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NCT02758587 · 2017-07-04
UNKNOWN
The Watch the Spot TrialNCT02623712 · 2017-03-06
COMPLETED
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung CancerNCT02410603 · 2016-12-01
COMPLETED
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ SystemNCT02370303 · 2014-08-01
COMPLETED
Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction ChemotherapyNCT02004184 · 2013-12-01
TERMINATED
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung CancerNCT00983307 · 2009-08-27
COMPLETED
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)NCT00654420 · 2008-03-19
COMPLETED
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)NCT00406302 · 2007-01-01
COMPLETED
Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung CancerNCT00349102 · 2006-07-01
COMPLETED
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)NCT00312975 · 2006-05-01
COMPLETED
Study of Tarceva and Targretin in Stage I-II Lung CancerNCT00125372 · 2005-12-01
COMPLETED
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung CancerNCT00125359 · 2005-08-01
COMPLETED
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given CyclophosphamideNCT00132522 · 2005-05-01
COMPLETED
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)NCT00050336 · 2002-12-01
TERMINATED
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung CancerNCT00047801 · 2002-10-01
COMPLETED
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung CancerNCT00040638 · 2002-07-01
COMPLETED
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00036647 · 2001-11-01
COMPLETED
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung CancerNCT00153842 · 2001-08-01
TERMINATED
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyNCT00035516 · 2001-02-01
COMPLETED

Common interventions

Trial status mix

COMPLETED17
TERMINATED3
UNKNOWN1

Phase mix

PHASE211
PHASE14
PHASE34
NA2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.